Correlation between Liver Metastases and the Level of PRL-3 mRNA Expression in Patients with Primary Colorectal Cancer by Kim, Nam Won et al.
pISSN 2093-7822   eISSN 2093-7830
www.coloproctol.org
Journal of the Korean Society of
Coloproctology
www.coloproctol.org 231
Correlation between Liver Metastases and the Level of 
PRL-3 mRNA Expression in Patients with Primary Colorectal 
Cancer
Nam Won Kim, Chong Woo Chu
1, Tae Sung Ahn, Chang Jin Kim
2, Dong Jun Jung
2, Myoung Won Son, 
Sang Ho Bae, Moon Soo Lee, Chang Ho Kim, Moo Jun Baek
Department of Surgery, Soonchunhyang University College of Medicine, Cheonan; 
1Department of Surgery, Pusan National University 
Yangsan Hospital, Yangsan; 
2Department of Pathology, Soonchunhyang University College of Medicine, Cheonan, Korea
Original Article
J Korean Soc Coloproctol 2011;27(5):231-236
http://dx.doi.org/10.3393/jksc.2011.27.5.231
Purpose: Phosphatase of regenerating liver-3 (PRL-3) has been associated with metastasis promotion. However, clinical 
applications of this association have not yet been clearly demonstrated. In this study, we evaluated the relation of PRL-3 
mRNA level in primary colorectal cancer to the corresponding stage and to other clinicopathologic factors.
Methods: Two hundred forty-five patients with histologically-proven colorectal cancer underwent surgery between Janu-
ary 2004 and December 2006. RNA was extracted and cDNA was prepared by using reverse transcription. Quantification 
of PRL-3 was done using a real-time polymerase chain reaction.
Results: Eighty-six cases with well-preserved specimens were enrolled: 53 males and 33 females. The mean age was 63.4 
years. According to tumour node metastasis (TNM) stage of the American Joint Committee on Cancer (AJCC), stage I was 
11 cases, stage II was 38 cases, stage III was 23 cases, and stage IV was 14 cases. Among stage IV cases, one case was com-
bined with liver and lung metastases, and one case was combined with liver metastases and peritoneal dissemination. The 
remaining stage IV patients were combined with only liver metastases. There was a significant correlation in PRL-3 mRNA 
expression between primary colorectal cancer and corresponding tumor stage. PRL-3 mRNA expression was increased in 
the liver metastases cases. Lymphatic and vascular invasion were significantly related with PRL-3 mRNA levels.
Conclusion: Advanced stage prediction may be obtained by measuring the level of PRL-3 mRNA expression in primary 
colorectal cancer. Especially, the risk of liver metastases may be predicted by measuring the level of PRL-3 mRNA expres-
sion in primary colorectal cancer. Further study is required to confirm these preliminary results.
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mechanisms for the metastases of malignant tumors, including 
colorectal cancer, has been found, but achieving a clear understand-
ing of the genes or materials causing metastasis is difficult.
Protein tyrosine phosphatase (PTP) is a material playing an es-
sential role in regulating various proteins involved in physiologi-
cal and other processes that cause diseases [1]. Unlike phosphory-
lation of serine or threonine, phosphorylation of the protein tyro-
sine is found only in eukaryotes. Phosphorylation of the protein 
tyrosine is important for the functions of eukaryotes, such as cell 
proliferation, cell differentiation, metabolism, intercellular com-
munication, cell movement, genetic transcription, immune re-
sponse and ion channeling [2]. Moreover, abnormal phosphoryla-
tion of tyrosine is related with various diseases, including cancer, 
diabetes, rheumatoid arthritis and hypertenstion. Phosphoryla-
tion of tyrosine is a reversible process and is regulated by the pro-
INTRODUCTION
Metastasis is a major cause of colorectal cancer death. Most of the 
patients die of metastatic disease rather than the primary colorec-
tal cancer. Through a number of studies, genetic and biochemical 
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tein tyrosine kinase (PTK), which is involved in the phosphoryla-
tion of two complimentary enzymes, and the PTP, which is the 
enzyme involved in dephosphorylation. Both PTK and PTP pro-
duce large protein families composed of many different enzymes 
[3, 4]. PTP can amplify or reduce intracellular signal transduction 
and is important for the functions of eukaryotes [5]. If the func-
tions of PTP are not well regulated, the development and progres-
sion of various diseases are promoted [6]. Among the proteins pro-
duced by PTP, phosphatase of regenerating liver (PRL) has 3 sub-
categories, PRL-1, PRL-2, and PRL-3, each of which has a size of 
roughly 20 KDa and a homology in amino acid structure of more 
than 75% [6, 7]. PRL-1 is known to be an immediate early gene con-
trolling regeneration of the liver [8]. Excessive expression of PRL-1 
or PRL-2 is known to promote tumor growth in nude mice [7].
PTP4A3, which is also known to be a phosphatase of regenerat-
ing liver-3, is a member of the PTP super family and is a gene re-
lated to progress, invasion and metastasis of malignant tumors [9-
11]. PRL-3 is a phosphatase having small molecular weight with a 
size of 22 KDa. Among human adult normal tissues, PRL-3 mRNA 
is mainly expressed in skeletal muscles or the heart and is expressed 
at low levels in the pancreas, spleen, lung and testis [10, 12]. The 
physiological functions of PRL-3 in those tissues have not yet been 
clarified.
The functions of members of the PRL family are understood to 
play important roles in the processes of initiation and development 
of tumors such as cancer cell invasion and migration, neovascu-
larization of tumors, and metastasis [9, 13-15]. A unique excessive 
expression of PRL-3 was initially observed in primary colorectal 
cancer tissues [13]. Later, excessive expression of PRL-3 was veri-
fied as promoting cellular migration, invasion and metastasis in 
Chinese hamster ovary cells [9]. In vivo and in vitro experiments 
confirmed that PRL-3 induced endothelial cells to initiate angio-
genesis of tumors and then to promote metastasis of the tumors 
[15]. Additionally, increased expression of PRL-3 has been reported 
to be related to the progression and metastasis of cancer in various 
tumors, such as breast cancer [16], ovarian cancer [17], and stom-
ach cancer.
In our previous study [18] on protein expression of PRL-3 in pri-
mary colorectal cancer tissues, we reported a higher level of pro-
tein expression of PRL-3 in primary colorectal cancer tissues with 
hepatic metastasis than in those without metastasis. In the present 
study, we tried to analyze the expression of PRL-3 mRNA in pri-
mary colorectal cancer tissues and its effects on the progression of 
colorectal cancer, especially its relation with the existence of hepatic 
metastasis, by using a real-time reverse transcription-polymerase 
chain reaction (RT-PCR) to quantitatively analyze PRL-3 mRNA 
expression. We compared the results of RT-PCR with various clin-
icopathological factors to determine if the existence of hepatic me-
tastasis could be predicted; in particular, we used PRL-3 expres-
sion in primary colorectal cancer tissues to find relations between 
hepatic metastasis and the clinicopathological factors.
METHODS
Patients
A total of 86 patients who visited Soonchunhyang University 
Cheonan Hospital, were histologically diagnosed with colorectal 
cancer and then underwent surgery between the period of Janu-
ary 2004 and December 2006 were enrolled in the present study. 
No patient received chemotherapy or radiation therapy prior to 
surgery, which was radical surgery. Excised tissues were immedi-
ately cooled by using liquid nitrogen and were kept frozen in a 
freezer at -80°C before extracting RNA. For staging, we followed 
the tumour node metastasis (TNM) classification of malignant 
tumors of the American Joint Committee on Cancer (AJCC), 7th 
edition, revised in 2010.
Methodology
RNA extraction and reverse transcription
The RNA of the colorectal cancer cells kept at -80°C was extracted 
using Totally RNA
TM (Ambion Inc., Austin, TX, USA) and was pu-
rified using RNeasy to prevent the extracted RNA from being mixed 
with DNA. The integrity of the extracted RNA was determined by 
using agar electrophoresis to analyze intact 18S/28S rRNA bands.
RNA was reverse transcribed to cDNA, together with oligo (dT) 
primer, by using a Power cDNA synthesis kit (Intron, Seongnam, 
Korea). One μg of RNA was cultured in 20 μL of solute (1 μL of 
RNase inhibitor, 4 μL of 5X RT buffer, 2 μL of dNTP, 2 μL of DTT, 
and 0.5 μL of AMV RT enzyme) at 42°C for 60 minutes. The RT 
reaction was conducted at 70°C for over 5 minutes.
Quantitative real-time detection of PCR
Quantitative real-time RT-PCR analyses were conducted using the 
ABI PRISM 7000 Sequence Detection System and the QuantiTect 
SYBR Green RT-PCR kit (Qiagen, Seoul, Korea). As a primer for 
amplifying the products of the reaction, forward 5´-GGG ACT 
TCT CAG GTC GTG TC-3´ and 5´-AGC CCC GTA CTT CTT 
CAG GT-3´ were prepared. As a primer for amplifying β-actin with 
a control material detecting RNA, forward 5´-CCA CGA AAC 
TAC CTT CAA CTC C-3´ and reverse 5´-TCA TAC TCC TGC 
TGC TTG CTG ATC C-3´ were used. According to the manufac-
turer’s instruction, master-mix (50 μL) was prepared with the com-
binations of 2 × QuantiTect SYBR Green RT-PCR Master Mix (25 
μL), each primer at 0.5 μmol/L, QuantiTect RT Mix (0.5 μL), total 
RNA (10 μL, 10 ng) and RNase-free water. Amplification was con-
ducted by repeating the process 40 times, which involved an initial 
30-minute reaction at 50°C, followed by 15-minute denaturation 
at 95°C, 15-minute denaturation at 94°C, 30-minute annealing at 
60°C, and 1-minute elongation at 72°C. All tests were repeated 2 
times.
Statistical analysis
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invasion, and its relation with neural invasion, lymphatic invasion, 
and vascular invasion were examined using the Mann-Whitney 
test in the SPSS ver. 12.0 (SPSS Inc., Chicago, IL, USA) program. 
Relations with staging and differentiation level of primary colorec-
tal cancer were analyzed using the ANOVA test and were evalu-
ated as being statistically significant when the P-value was less 
than 0.05.
RESULTS
Patients characteristics
The 86 subjects included 53 males and 33 females, with ages rang-
ing from 34 to 92 years and a mean age of 64.35 years. According 
to the TNM classification of malignant tumors of the AJCC, 11 
subjects were in stage I (12.8%), 38 were in stage II (44.2%), 23 
were in stage III (26.7%), and 14 were in stage IV (16.3%). In terms 
of cell differentiation, moderately differentiated cancer had the 
greatest number of 67 (77.9%). Out of 14 cases in stage IV, 1 case 
had both liver and lung metastases, another case had both liver 
metastasis and intraperitoneal dissemination, and the remaining 
cases had liver metastases only (Table 1).
Relation between the level of mRNA expression in primary 
colorectal cancer tissues and clinicopathological factors
The level of expression of PRL-3 mRNA in primary colorectal can-
cer tissues and various clinicopathological factors in the colorectal 
cancer patients were compared. Stage, lymph-node invasion, vas-
cular invasion, lymphatic invasion, neural invasion, cell differenti-
ation and survival rates were compared, Among these, amount of 
PRL-3 mRNA was significantly higher in cases involving lymphatic 
invasion cancer cells (P = 0.021) and vascular invasion (P = 0.001) 
by cancer cells. In terms of stage, the larger the amount of PRL-3 
mRNA expression was, the more advanced the stage was (P < 0.001) 
(Fig. 1). However, in terms of neural invasion (P = 0.563) and can-
cer cell differentiation (P = 0.887), no significant differences were 
found in the amount of PRL-3 mRNA (Table 2). Additionally, no 
significant difference was found in terms of the age or the sex of 
the patients.
Relation between the level of mRNA expression in primary 
colorectal cancer tissues and hepatic metastasis of colorectal 
cancer
The level of PRL-3 mRNA expression in primary colorectal can-
cer tissues and the presence of hepatic metastasis of colorectal can-
cer were compared, and an increase in the amount of PRL-3 mRNA 
expression was confirmed to be related to an increase in hepatic 
metastasis of colorectal cancer (P = 0.05) (Fig. 2).
DISCUSSION
Most deaths from colorectal cancer are caused by metastasis, not 
by the primary colorectal cancer itself. However, the molecular 
Table 1. Clinicopathological variables of patients
Characteristics Frequency (%)
Age (yr), mean ± SD 64.87 ± 11.74
Gender
   Male 53 (61.6)
   Female 33 (38.4)
Histology
   Well differentiated 6 (7.0)
   Moderately differentiated 67 (77.9)
   Poorly 8 (9.3)
   Unknown 5 (5.8)
Lymphatic invasion
   No 70 (81.4)
   Yes 16 (18.6)
Vascular invasion
   No 71 (82.6)
   Yes 15 (17.4)
Neural invasion
   No 78 (90.7)
   Yes 8 (9.3)
Stage
   I 11 (12.8)
   II 38 (44.2)
   III 23 (26.7)
   IV 14 (16.3)
Fig. 1. Box plots of the phosphatase of regenerating liver (PRL) level 
of colorectal cancer according to tumour node metastasis (TNM) stage. 
The Y axis is represented by a logarithmic scale.
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biological mechanism regulating metastasis of colorectal cancer is 
still unknown. As reported by Vogelstein for the first time, various 
tumor suppressor genes and oncogenes are involved in the devel-
opment process from a normal colorectal mucosa to an early ade-
noma, an advanced adenoma and finally malignant colorectal can-
cer, but the genes involved in metastasis after the development of 
a malignant tumor have not yet been identified.
PTPs play a fundamental role in regulating diverse proteins that 
participate essentially in every aspect of physiological and patho-
genic cellular processes [1]. The PRL phosphatases (PRL-1, -2, and 
-3) are three closely related intracellular enzymes that possess PTP 
active sites and are believed to play key roles in cellular transforma-
tion. Like the PTP active site signature sequence CX5R, they are 
molecules having a unique COOH-terminal prenylation motif [19]. 
These PTPs have a size of roughly 20 KDa and share a 75% amino 
acid sequence similarity [7]. According to various research, PRL-3 
plays an important role during invasion and metastasis of tumors 
[9, 10, 13, 17]. However, the role of PRL-3 in the carcinogenesis 
and progression of colorectal cancer has not yet been clarified.
According to the present study, tissues from patients having 
colorectal cancer with hepatic metastasis were confirmed to show 
higher levels of phosphatase PRL-3 than tissues from patients hav-
ing colorectal cancer without metastasis. Phosphatase PRL-3 was 
also confirmed to have relations with aggressive factors of cancer, 
such as lymphatic or vascular invasion, and with the stage of colo-
rectal cancer.
When PRL-3 is excessively expressed in a human malignant tu-
mor, the PRL-3 gene is located in the human chromosome 8q. In 
3 of 12 metastases examined, multiple copies of the PRL-3 gene 
were found within a small amplicon located at chromosome 8q24.3. 
Moreover, extra copies of this region are often found in advanced 
stages of different tumor types. Thus, PRL-3 genes may be assumed 
to play an important role in metastasis of various malignant tu-
mors, including colorectal cancer [13, 20, 21]. Further, according 
to recent studies, PRL-3 is related with PI3K-Akt, STAT3-Rho, 
Csk/Src and p53 signal transduction pathways [22-25]. Upon ver-
ifying the signal transduction pathway in the future, extensive in-
formation on molecular biology regarding the effect of PRL-3 on 
the progression of cancer, specifically on hepatic metastasis, may 
be obtained.
PRL-3 has been understood as being a gene related with metas-
tasis of colorectal cancer. In the present study, we wanted to con-
firm the relation between mRNA expression of PRL-3 and colorec-
tal cancer with hepatic metastasis, specifically primary colorectal 
cancer with hepatic metastasis. We confirmed that the expression 
level of PRL-3 mRNA was related with the progression of colorec-
tal cancer. More specifically, we confirmed that excessive expres-
sion of PRL-3 mRNA in tissues of the primary colorectal cancer 
Fig. 2. Box plot of the phosphatase of regenerating liver (PRL) level of 
colorectal cancer according to hepatic metastasis. The Y axis is repre-
sented by a logarithmic scale. 
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Table 2. Mean phosphatase of regenerating liver (PRL) gene expres-
sion levels in colorectal carcinomas
No.   PRL expression levels P-value
Gender 0.546
   Male 53     18.18 ± 108.71
   Female 33     34.61 ± 141.14
Histology 0.887
   Well differentiated   6   1.52 ± 2.13
   Moderately differentiated 67     29.84 ± 131.17
   Poorly differentiated   8   0.83 ± 0.79
   Unknown   5     24.87 ± 125.07
Lymphatic invasion 0.021
   + 70     26.02 ± 133.74
   - 16   17.79 ± 38.67
Vascular invasion 0.001
   + 71     26.94 ± 127.54
   - 15 0.611 ± 0.50
Neural invasion 0.563
   + 78     25.60 ± 132.83
   -   8   19.21 ± 39.61
Stage <0.001
   I 11   0.68 ± 0.70
   II 38   0.39 ± 0.41
   III 23   1.00 ± 0.99
   IV 14   147.20 ± 278.14
Liver metastasis 0.05
   No 72   0.63 ± 0.73
   Yes 14   147.20 ± 278.14
Values are presented as mean ± SD. Journal of The Korean Society of
Coloproctology
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was related with hepatic metastasis of colorectal cancer.
According to initial research on the expression of PRL-3 in colo-
rectal cancer, this enzyme is not expressed in the early stage of tu-
mor development, but is expressed only in metastasized cancer 
cells [14], so PRL-3 is found neither in the normal mucosa nor in 
colorectal cancer without metastasis. Interpretations of the effects 
of PRL-3 on cell growth do not agree among various reports. Ac-
cording to a study, for example, ectopic expression of PRL-3 pro-
motes cell proliferation [7, 26], but according to another study us-
ing the DLD-1 colon cancer cell line, temporary down regulation 
of PRL-3 by small interfering RNA does not seemingly affect cell 
proliferation [27]. Polato et al. [17] reported that when PRL-3 siRNA 
was incorporated into the HCT-116 colon cancer cell line, cell growth 
was not affected, even though a low level of PRL-3 was expressed.
Various researchers expect PRL-3 expression to be required for 
metastasis of a tumor in its early stage, for which lymphatic and 
vascular invasion has occurred [27]. Other researchers found that 
PRL-3 might be used as a tumor marker for metastasis of colorec-
tal cancer through immunostaining and that expression of PRL-3 
might adversely affect the prognosis for a colorectal cancer patient 
[28]. Recent studies have reported many cases with unfavorable 
effects of expression of PRL-3 on breast cancer, ovarian cancer and 
stomach cancer [17, 29].
According to the recent study of Radke et al. [16], the disease-
free survival rate of lymph-node-metastasized breast cancer pa-
tients with excessive expression of PRL-3 was significantly lower 
than that of patients without PRL-3 expression. However, the same 
authors’ previous study showed no difference in survival rates when 
expression of PRL-3 using immunostaining was compared with 
the cases of colorectal cancer patients [18].
In our previous study, we confirmed the expression of PRL-3 in 
primary colorectal cancer tissues by using immunohistochemical 
staining, and we compared the results with factors such as age, sex, 
size of tumor, cancer cell differentiation, depth of invasion, micro-
scopic findings of lymphatic metastasis, hematogenous metastasis, 
number of lymph-node metastases, post-operative tumor stages 
and survival rates through a retrospective study to find correlations 
between those factors and PRL-3 expression. As a result, PRL-3 
expression showed a significant relation with lymphatic invasion 
and T stage of the tumor [18]. In addition, in 15 cases out of a total 
of 16 hepatic metastasis cases, positive expression of PRL-3 showed 
a correlation with hepatic metastasis. Even though we could not 
obtain exact survival rates in the present study, considering the ad-
verse effects of correlations among PRL-3 and clinicopathological 
factors on the survival rates, PRL-3 expression in primary colorec-
tal cancer is evidently related with a worse prognosis for colorectal 
patients.
According to our study, PRL-3 may be an important factor con-
tributing to the invasion and metastasis of colorectal cancer cells. 
A high level of expression of PRL-3 mRNA was found in the pri-
mary colorectal cancer tissues of a colorectal cancer patient with 
hepatic metastasis, and expression of PRL-3 mRNA is understood 
to affect lymphatic and vascular invasion and stages of colorectal 
cancer. Thus, PRL-3 plays an important role in the progression, 
invasion and metastasis of primary colorectal cancer. Consequently, 
PRL-3 may possibly be used as a marker for measuring the pro-
gression and invasion of colorectal cancer. In addition, PRL-3 may 
also be used as a target for developing methods of treating meta-
static colorectal cancer, which is still difficult to cure.
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